Update

Although DepoTech Corp.'s fall can be traced to a blow-up at an FDA advisory panel review, the agency's approach to advisory committee management under the new era of the FDA Modernization Act is still undetermined.

In theory, under FDAMA, DEPO may have been able to avoid the rebuff of its DepoCyt sustained-release cytarabine that it was handed last December by the Oncologic Drugs Advisory Committee...